A new vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme
- 1 January 2007
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (1), 191-193
- https://doi.org/10.1111/j.1538-7836.2006.02261.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dosePharmacogenetics and Genomics, 2005
- A vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with vitamin K antagonist resistanceJournal of Thrombosis and Haemostasis, 2005
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarinBlood, 2005
- Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1Thrombosis and Haemostasis, 2005
- Discovery of new potentially defective alleles of human CYP2C9Pharmacogenetics, 2004
- Vitamin K epoxide reductase: homology, active site and catalytic mechanismTrends in Biochemical Sciences, 2004
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994